Loading…
Sakar Healthcare (SAKAR)₹1,029+2.43%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Sakar Healthcare reported sales of ₹86.88 Cr, up 49.9% from Sep 2025, and net profit of ₹11.01 Cr, up 119.8% year on year. For the year to Mar 2026, sales were ₹251 Cr and net profit ₹30.06 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 36.97 | 42.96 | 40.94 | 42.93 | 42.98 | 49.93 | 52.92 | 57.97 | 69.97 | 70.95 | 72.88 | 86.88 |
| Expenses | 27.89 | 31.89 | 29.87 | 30.90 | 31.87 | 34.87 | 39.87 | 45.84 | 51.77 | 44.83 | 51.77 | 62.81 |
| Operating Profit | 9.03 | 11.03 | 11.04 | 12.04 | 12.04 | 16.06 | 13.03 | 11.03 | 19.05 | 26.07 | 21.06 | 24.08 |
| OPM % | 24.0% | 25.0% | 26.0% | 26.9% | 26.9% | 31.0% | 23.9% | 19.9% | 25.9% | 37.0% | 28.9% | 27.9% |
| Other Income | 0.00 | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 | 0.00 | 1.99 | 0.00 |
| Interest | 1.99 | 1.99 | 0.99 | 1.99 | 0.99 | 3.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 | 1.99 |
| Depreciation | 3.99 | 4.98 | 4.99 | 4.99 | 4.99 | 4.99 | 5.99 | 5.99 | 5.98 | 5.99 | 6.98 | 6.98 |
| Profit before tax | 3.01 | 5.02 | 5.02 | 5.02 | 5.02 | 6.02 | 5.02 | 5.02 | 11.05 | 18.06 | 15.06 | 16.05 |
| Tax % | 31.0% | 35.1% | 49.1% | 6.0% | 17.0% | 8.0% | 13.1% | 15.1% | 6.0% | 39.0% | 29.0% | 29.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 2.01 | 3.01 | 2.01 | 5.01 | 5.01 | 6.02 | 5.01 | 5.01 | 10.02 | 11.02 | 10.02 | 11.01 |
| EPS (Rs) | 0.94 | 1.44 | 1.10 | 2.22 | 2.07 | 2.61 | 2.11 | 2.05 | 4.62 | 4.94 | 4.63 | 5.07 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales | 82.97 | 94.91 | 128 | 133 | 153 | 178 | 251 | 301 |
| Expenses | 62.76 | 71.78 | 98.57 | 99.59 | 115 | 128 | 181 | 211 |
| Operating Profit | 20.06 | 23.08 | 29.08 | 33.12 | 38.10 | 50.18 | 69.17 | 90.26 |
| OPM % | 23.9% | 23.9% | 23.0% | 25.0% | 25.0% | 28.0% | 27.0% | 30.0% |
| Other Income | 1.99 | 0.99 | 1.99 | 4.99 | 2.99 | 0.99 | 1.99 | 2.98 |
| Interest | 1.99 | 1.99 | 2.99 | 5.98 | 7.97 | 8.97 | 7.98 | 7.96 |
| Depreciation | 6.98 | 7.98 | 9.98 | 14.97 | 17.94 | 20.94 | 23.94 | 25.93 |
| Profit before tax | 12.04 | 13.05 | 19.08 | 17.06 | 16.05 | 22.09 | 40.14 | 60.22 |
| Tax % | 21.0% | 19.0% | 20.0% | 24.1% | 27.1% | 19.1% | 23.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 10.01 | 11.02 | 15.02 | 13.03 | 12.03 | 18.05 | 30.06 | 42.07 |
| EPS (Rs) | 6.44 | 6.85 | 8.91 | 6.69 | 5.38 | 7.96 | 13.69 | 19.26 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 14.94 | 15.93 | 16.92 | 18.91 | 21.90 | 21.90 | 21.90 |
| Reserves | 65.93 | 83.10 | 110 | 154 | 240 | 263 | 302 |
| Borrowings | 16.98 | 43.00 | 92.74 | 119 | 78.81 | 85.79 | 70.89 |
| Other Liabilities | 16.91 | 36.82 | 46.78 | 43.79 | 46.78 | 42.79 | 85.60 |
| Total Liabilities | 115 | 178 | 267 | 335 | 388 | 414 | 480 |
| Fixed Assets | 65.72 | 68.77 | 204 | 266 | 313 | 308 | 325 |
| CWIP | 13.06 | 49.18 | 1.01 | 6.02 | 0.00 | 17.05 | 4.01 |
| Investments | 0.00 | 0.00 | 6.98 | 2.99 | 0.00 | 0.00 | 0.00 |
| Other Assets | 35.98 | 59.90 | 54.94 | 59.91 | 73.89 | 89.83 | 151 |
| Inventories | 10.98 | 15.99 | 13.98 | 14.99 | 27.97 | 43.95 | 69.87 |
| Trade receivables | 7.99 | 11.97 | 13.98 | 21.97 | 20.95 | 30.92 | 49.94 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Assets | 115 | 178 | 267 | 335 | 388 | 414 | 480 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 19.08 | 15.07 | 36.16 | 33.12 | 24.10 | 34.11 | 49.20 |
| Cash from investing activity | −21.96 | −46.92 | −89.83 | −73.82 | −51.87 | −30.91 | −27.91 |
| Cash from financing activity | 2.99 | 31.87 | 54.84 | 40.86 | 26.93 | −2.99 | −20.93 |
| Net cash flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Capex | 22.36 | 46.78 | 97.34 | 82.08 | 59.44 | 32.24 | 28.32 |
| Free cash flow | −4.01 | −32.02 | −62.03 | −49.03 | −34.98 | 2.01 | 20.99 |
| CFO / OP % | 110.0% | 67.0% | 120.0% | 113.0% | 72.0% | 73.0% | 77.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 37 | 49 | 41 | 61 | 51 | 64 | 74 |
| Inventory days | 92 | 112 | 69 | 76 | 121 | 193 | 207 |
| Days payable | 46 | 141 | 149 | 129 | 120 | 93 | 153 |
| Cash conversion cycle | 83 | 19 | −39 | 7 | 51 | 163 | 127 |
| Working capital days | 31 | 1 | −11 | −6 | 29 | 52 | 45 |
| ROCE % | — | 13.0% | 12.0% | 8.9% | 7.0% | 8.9% | 12.0% |
For the Sep 2026 quarter, Sakar Healthcare reported sales of ₹86.88 Cr, up 49.9% year on year and net profit of ₹11.01 Cr, up 119.8% year on year. The operating margin was 27.9%.
Sakar Healthcare's sales for the year to Mar 2026 were ₹251 Cr; over the last twelve months they were ₹301 Cr.
Net profit for the year to Mar 2026 was ₹30.06 Cr, and ₹42.07 Cr over the last twelve months. Earnings per share over the same trailing period were ₹19.26.
Sakar Healthcare reported borrowings of ₹70.89 Cr at Mar 2026, against cash and equivalents of ₹0 Cr.
Cash from operations was ₹49.20 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹20.99 Cr.